Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...

Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Pasithea Therapeutics Corp (NASDAQ: KTTA) shares are trading sharply higher Wednesday following a string of upbeat updates.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

The human body experiences various health problems because of inflammation, which can lead to joint pain, heart disease and ...

Genfleet Therapeutics (Shanghai), Inc. Class H ( ($HK:2595) ) just unveiled an announcement. GenFleet Therapeutics has initiated the first ...

Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. On November 28, 2025, Pasithea Therapeutics Corp announced a public offering of ...

Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge ...

Erasca, Inc. (NASDAQ:ERAS) is one of the 12 hot penny stocks to invest in right now. On November 14, 2025, Erasca, Inc.

Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

In this piece, we will discuss the 12 hot penny stocks to invest in right now. Amid an uncertain macro environment, where the economic outlook is blurry, the momentum of penny stocks depends heavily ...